Latest news and press releases about Damora Therapeutics, Inc. (GLTO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.68 |
| EV / EBITDA | 1.90 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -82.56% |
| Return on Invested Capital | -52.44% |
| Return on Assets | -48.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks